Alternate Title: National Institute of Allergy and Infectious Diseases
"This updated Strategic Plan for Biodefense Research builds upon the successes and investments of the first plan and accompanying research agendas; it is consistent with the HHS [Department of Health and Human Services] Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy for Chemical, Biological, Radiological and Nuclear Threats, the HHS PHEMCE Implementation Plan, and the Homeland Security Presidential Directive (HSPD)-18, which outline strategies for identifying medical countermeasure requirements and establishing priorities for their research, development, and acquisition. These successes and investments include advances in understanding the biology of specific pathogens and the host's immune response; construction of new biocontainment laboratory facilities; professional training in biosafety and biocontainment; and establishment of critical research resources and infrastructure that support applied science and advanced product development. Although the focus of this updated Strategic Plan continues to be on basic research and its application to product development, there is a shift from the current 'one bug-one drug' approach toward a more flexible, broad spectrum approach. This approach involves developing medical countermeasures that are effective against a variety of pathogens and toxins, developing technologies that can be widely applied to improve classes of products, and establishing platforms that can reduce the time and cost of creating new products. The broad spectrum strategy recognizes both the expanding range of biological threats and the limited resources available to address each individual threat."
National Institute of Allergy and Infectious Diseases : http://www.niaid.nih.gov/publications/